Claude designed working drug molecules for 14 of 15 targets
&imwidth=600&imheight=450&format=webp&quality=medium "Claude designed working drug molecules for 14 of 15 targets")
Claude designed working drug molecules for 14 of 15 targets
Anthropic reports that Claude autonomously designed protein binders against 15 clinically significant targets, including PD-L1, TREM2, TNF-alpha and EGFR. Fourteen produced at least one confirmed binder. Adaptyv Bio and Twist Bioscience synthesised and tested the designs without modification, measuring hit rates of 22.6 to 35.1 per cent against an industry baseline of 10 to 15 per cent.
Most claims about AI in drug discovery are claims about software. This one was tested in a laboratory by people who did not write it.
Anthropic reports that Claude ran autonomous protein binder design campaigns against 15 clinically significant targets. Fourteen produced at least one binder that worked. The designs were synthesised and tested by Adaptyv Bio and Twist Bioscience without modification.
What A Binder Is, And Why This Is Hard
A large number of drugs work by binding to a specific protein in the body and blocking or altering what it does. Designing a molecule that attaches tightly to a chosen target, and only to that target, is the first step of the process and one of the most difficult.
Done conventionally, it takes weeks or months of specialist work per target, and most attempts fail. The industry baseline for designing binders from scratch — de novo, without starting from a known molecule — is a success rate of roughly 10 to 15 per cent.
Claude's campaigns produced confirmed binders at rates between 22.6 and 35.1 per cent, depending on how the sessions were structured. That is somewhere between one and a half and three times the conventional rate.
Trending Stories
&im=FitAndFill=(700,400))
)
)
)
)
&im=FitAndFill=(700,400))
)
)
)
)
)
)
)
)
)
)
)
&im=FitAndFill=(700,400))
)
)
)
)
)
&im=FitAndFill=(700,400))
)
)
)
)
)
&im=FitAndFill=(700,400))
)
)
)
The Targets Were Not Easy Ones
The choice of targets matters, because success against trivial proteins would prove nothing.
The 15 included PD-L1, the checkpoint protein at the centre of modern cancer immunotherapy; TREM2, implicated in Alzheimer's disease; TNF-alpha, the target of anti-inflammatory drugs including Humira, one of the best-selling pharmaceuticals ever made; and EGFR, a long-established oncology target.
These are proteins that pharmaceutical companies have spent decades and enormous sums working on. They were chosen because they are clinically consequential and well characterised, which means the results can be judged against a substantial body of existing work.
Why The Wet Lab Matters More Than The Model
The most important detail is not the hit rate. It is who measured it.
Computational biology has a long history of impressive predictions that did not survive contact with a laboratory. A model can propose a structure that scores well against its own objective and simply fails to fold, bind or remain stable when actually synthesised. The field's credibility problem has always been the gap between prediction and physical confirmation.
Adaptyv Bio and Twist Bioscience are independent companies that build and test proteins. They took Claude's designs as submitted, made them, and measured whether they bound. That is external validation of a physical result, which is a materially different claim from a benchmark score.
The word autonomous is doing real work too. This was not a researcher using a model as an assistant. Claude ran the campaigns — proposing candidates, evaluating them, iterating — which is a claim about a workflow rather than a single output.
The Appropriate Caution
Several things this result is not.
It is not a drug. A binder that attaches to its target in a laboratory assay is separated from a medicine by years of work on selectivity, stability, toxicity, manufacturing, delivery and clinical trials in humans. The overwhelming majority of molecules that bind correctly never become treatments, and that attrition is where pharmaceutical economics actually lives.
It is also research published by the company that makes the model. Anthropic has released a paper and the collaborators have published their own account, which is considerably better than a press release, but this is not yet independent replication by unaffiliated academic groups. That is the standard the result will ultimately be held to.
And a hit rate is a comparison against a baseline that depends on how it is defined. Industry figures for de novo binder design vary by target class, by method and by who is reporting them.
What It Would Change If It Holds
The significance is not that an AI can do what protein designers do. It is where the bottleneck moves if it can.
The rate-limiting step in early drug discovery has been the number of credible candidate molecules a team can generate and test. Expert time is the scarce input, and it is why programmes concentrate on targets commercially large enough to justify the expense. Rare diseases go unaddressed not because the biology is impossible but because nobody can fund the search.
A system that generates candidates at two to three times the conventional hit rate, without consuming specialist months per target, moves the constraint to synthesis and testing capacity — which is equipment and money rather than scarce human expertise, and scales differently.
That is the case for taking this seriously, and it is why the wet-lab confirmation matters more than any benchmark Anthropic could have published.
It also arrives in a week when the same company was graded zero on its published plan for containing a model that escapes control. Both things are true about the same technology, and the second is not an argument against the first. It is the reason the first is worth getting right.
